Skip to main content
. 2013 Dec 4;306(3):F359–F366. doi: 10.1152/ajprenal.00330.2013

Fig. 2.

Fig. 2.

Urine osmolality measurements in the in vivo tolvaptan model. Shown is urine osmolality (means ± SE) for tolvaptan (2.5 mg/day infusion rate) and control groups after minipump insertion, for 4 days; n = 5 for both control and tolvaptan groups.